KINNATE BIOPHARMA INC.
KINNATE BIOPHARMA INC. (KNTE): 2 pipeline candidates · ~26 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
26.0 months
D/E 0.09 · 0% dilution
Lead: Phase 1
2 candidates
N/A
N/A
A transparent, data-derived signal for KINNATE BIOPHARMA INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$57.4M
Quarterly Burn
$17.4M
Runway
26.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in KINNATE BIOPHARMA INC.'s pipeline?
KINNATE BIOPHARMA INC. (KNTE) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is KINNATE BIOPHARMA INC.'s lead drug candidate?
KINNATE BIOPHARMA INC.'s most advanced tracked candidate is kin-2787 (Phase 1) for lung cancer, melanoma and other solid tumors.
What is KINNATE BIOPHARMA INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, KINNATE BIOPHARMA INC. has approximately 26.0 months of cash runway.
Who is the CEO of KINNATE BIOPHARMA INC.?
Nima Farzan is the chief executive officer of KINNATE BIOPHARMA INC. (KNTE).
Get the full picture on KINNATE BIOPHARMA INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.